Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?
Open Access
- 2 April 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 23 (8) , 2450-2453
Abstract
The introduction of erythropoiesis-stimulating agents (ESA), such as recombinant human erythropoietin (EPO) has allowed effective treatment of anaemia in patients with chronic kidney disease (CKD). However, the optimal target level of haemoglobin is debated and many patients are resistant to ESA.Keywords
This publication has 35 references indexed in Scilit:
- Hepcidin: from discovery to differential diagnosisHaematologica, 2008
- Regulation of iron acquisition and storage: consequences for iron-linked disordersNature Reviews Molecular Cell Biology, 2008
- Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)Journal of Clinical Investigation, 2007
- Suppression of hepcidin during anemia requires erythropoietic activityBlood, 2006
- Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrationsBlood, 2006
- Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its InternalizationScience, 2004
- Hepcidin, A New Iron Regulatory PeptideBlood Cells, Molecules, and Diseases, 2002
- The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammationJournal of Clinical Investigation, 2002
- A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron OverloadJournal of Biological Chemistry, 2001
- Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the LiverJournal of Biological Chemistry, 2001